Neuren Receives Notice of Allowance for Two New Patents

Australia, 12 July 2013: Neuren Pharmaceuticals Limited (ASX:NEU) is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two new patents. The first covers oral formulations of NNZ-2566 and the second covers use of NNZ-2591 for the treatment of peripheral neuropathy.

The new patents will provide protection for additional methods of formulating NNZ-2566 for oral administration and for a new therapeutic use for NNZ-2591. The expiry date of the NNZ-2566 patent will be 2027. The NNZ-2591 patent will expire in 2031. Notably, both new patents relate to treatment of chronic conditions with oral forms of the molecules.

Seven patents for composition, methods of use and formulation have previously been issued for NNZ-2566 and three patents for composition and methods of use have been issued for NNZ-2591.

"As Neuren expands its emphasis on development of therapies for chronic neurological disorders, these patents will further enhance the commercial value of Neuren's drug pipeline," commented Larry Glass, Neuren's CEO.

About NNZ-2566
NNZ-2566 is a synthetic analogue of a naturally occurring neuropeptide derived from IGF-1, a growth factor produced by brain cells. In animal models, NNZ-2566 inhibits neuroinflammation and normalises the function of microglia with consequent improvements in molecular, cellular, anatomic and behavioural outcomes. NNZ-2566 is being developed both in intravenous and oral formulations for a range of acute and chronic conditions. The intravenous form of NNZ-2566 is presently in a Phase II clinical trial in patients with moderate to severe traumatic brain injury, which has received Fast Track designation from the US FDA, as well as a Phase II trial in Rett Syndrome. The company intends to implement a Phase II clinical trial in Fragile X Syndrome and an additional Phase II trial with the oral form of NNZ-2566 in patients with concussion or mild TBI.

About NNZ-2591
NNZ-2591 is a synthetic analogue of a naturally occurring neuropeptide which has been shown to have neuroprotective and nootropic (memory enhancing) effects in multiple animal models. NNZ-2591 has been shown to be neuroprotective in vitro in cytotoxicity tests, reduce infarct size in in vivo rodent models of stroke and hypoxia-ischemia, improve behavioural outcome following repeated treatment in Parkinsonian rats, exhibit nootropic effects in cognitively-impaired rats and provide significant protection against the development of peripheral neuropathy. NNZ-2591 has excellent oral bioavailability and is currently being assessed as a clinical candidate for the treatment of chronic neurological disorders.
Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile-X Syndrome as well as acute neurological injuries. Neuren presently has a clinical-stage molecule, NNZ-2566 in two Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development. Neuren currently has operations in New Zealand and the United States.

For more information, please contact:

Larry Glass, CEO
lglass@neurenpharma.com
Tel: +1 301 941 1830

Dr Richard Treagus, Executive Chairman
rtreagus@neurenpharma.com
Tel: +61 417 520 509